The Peruvian government has declared a state of emergency after 165 people recently came down with Guillain-Barre syndrome. That may not sound like a lot, but it has overwhelmed the healthcare system in Peru.

The “outbreak” has been so severe that the country’s strained healthcare system can’t even keep up with all the cases.

Oh, my gosh! It’s a medical mystery! Who can help solve it?

Guillain-Barre syndrome, like myocarditis, is one of those extremely rare conditions that nobody ever heard of prior to the COVID vaccine rollout in 2021. Everybody knows what myocarditis is today. It’s inflammation of the heart, causing heart muscle to die permanently and shaving years off the patient’s life. It’s not a mild or temporary condition, contrary to the lying media and the CDC.

Guillain-Barre syndrome, which often results in characteristic facial paralysis, is a neurological condition that is so rare that you are unlikely to ever encounter someone with it in your entire life. I’ve seen two people with the condition at my local grocery store within the last few weeks but can’t remember ever seeing anyone with it at any time previously in my life. There used to only be about 3,000 cases a year in America, or roughly 1 in 100,000.

It’s a serious condition, too. Four of the people diagnosed with it in Peru died. Some patients had to be airlifted to take them to an emergency clinic.

Guillain-Barre syndrome is an extremely rare neurological condition in which the immune system attacks part of the peripheral nervous system. Facial paralysis is just one symptom.

After a person comes down with it, they often develop either a gastrointestinal infection or a respiratory infection. The respiratory infection is usually the part that kills people, when they lose the ability to draw breath and suffocate.

The droopy facial paralysis on one side is the most obvious symptom. It’s what tanked Canadian pop star Justin Bieber’s world tour last year, and probably his entire singing career.

When Bieber became the poster boy for this rare condition that was popping up all over, researchers quickly sought to find a connection to COVID-19—rather than to the actual culprit.

Studies purported to show that the spike protein in the coronavirus was causing all these sudden outbreaks of Guillain-Barre syndrome. They didn’t pause to consider the fact that people weren’t getting Guillain-Barre syndrome during the first year of the pandemic, or that this only started happening after the vaccine rollout. That’s not how The Science is done! COVID is also the leading cause of coincidences, as we all know.

Peru normally only sees about 300 cases of Guillain-Barre syndrome over the course of a calendar year. Now they’ve seen 165 cases in the past month, with four fatalities, and the healthcare system is running out of medicines and supplies to treat it.

Under the government’s state of emergency declaration, they’re spending the equivalent of $3.3 million to order stashes of immunoglobin and albumin.

Albumin is a human liver enzyme used to restart a patient’s liver when it shuts down. Apparently, that’s become an associated symptom with the “outbreak” of Guillain-Barre syndrome. If a healthcare system runs out of albumin and immunoglobin for transfusions, it affects many patients in addition to the extra surprise patients with the syndrome.

The Sinopharm, Pfizer/BioNTech, Moderna, and Oxford/AstraZeneca COVID vaccines are the ones that have been used for the mass vaccination campaign in Peru. Both the Pfizer and Moderna jabs have been associated with increased risk of Guillain-Barre syndrome. The Johnson & Johnson vaccine has an even higher correlation, although that particular jab is not available in Peru.

One study of Guillain-Barre syndrome after vaccination that was published in the Journal of the American Medical Association (JAMA) found that 295 of the study participants developed the syndrome between 21- and 42-days post-vaccination. The vast majority of them (more than 65%) were whites. 93% required hospitalization. You can see that JAMA study HERE.

Peru is now having to publish informative materials to send to healthcare clinics across the country about Guillain-Barre syndrome. The condition used to be so rare that many clinics had never seen a case. 75% of the country’s health departments have now seen cases in the past month, and the system is overwhelmed. Great job, health officials!